Altimmune, Inc. (ALT) vs Arvinas, Inc. (ARVN)
A side-by-side comparison of Altimmune, Inc. and Arvinas, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALT
Altimmune, Inc.
$2.66HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT
ARVN
Arvinas, Inc.
$7.38HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT
Total return — ALT vs ARVN
growth of $100 · dividends reinvested · last 8yALT -78.0% (-17.2%/yr)ARVN -53.5% (-9.1%/yr)ARVN compounded faster over this window
ALT ARVN
ALT vs ARVN: by the numbers
- •ALT is the larger company ($517M vs $476M market cap).
- •ARVN is profitable (2.94% net margin) while ALT runs a net loss (-296000.00%).
- •ARVN grew revenue faster over the past five years (72.38% vs -65.38% CAGR).
Metrics side by side
Valuation
| Metric | ALT | ARVN |
|---|---|---|
| P/E ratio | N/A | 46.12 |
| P/S ratio | 16687.12 | 1.50 |
| P/B ratio | 1.09 | 0.85 |
Profitability
| Metric | ALT | ARVN |
|---|---|---|
| Gross margin | 100.00% | 96.43% |
| Operating margin | -230460.98% | -43.75% |
| Net margin | -296000.00% | 2.94% |
| ROE | -19.35% | 1.65% |
| ROIC | -19.47% | -2.19% |
Growth (annualized)
| Metric | ALT | ARVN |
|---|---|---|
| Revenue CAGR (5Y) | -65.38% | 72.38% |
| Total return CAGR (5Y) | -25.30% | -38.16% |
Frequently asked
- Which has grown faster, ALT or ARVN?
- Over the past five years, ARVN grew revenue faster — ALT at a -65.38% CAGR versus ARVN at 72.38%.
- Is ALT or ARVN more profitable?
- ARVN runs the higher net margin — ALT at -296000.00% versus ARVN at 2.94%.
- How have ALT and ARVN total returns compared?
- Over the past 5 years, ALT delivered -25.30% and ARVN delivered -38.16% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Arvinas P/E ratioAltimmune ROEArvinas ROEAltimmune operating marginArvinas operating marginAltimmune revenue growthArvinas revenue growthAltimmune free cash flowArvinas free cash flow
Altimmune & Arvinas appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.